VKTX earnings: next report 2026-07-29, real EPS beat/miss history, analyst consensus Buy, P/E -9.01. Updated 2026-07-23.
Viking Therapeutics (VKTX) Research Hub
Viking Therapeutics (VKTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 31.98 USD (-2.20%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -9.01, market cap 4.30B. This hub links to the full technical, earnings and options research available for VKTX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 31.98 USD (-2.20%) |
| 52-week range | 29.04 USD – 42.79 USD |
| Trend regime | Range |
| 14-day RSI | 42.3 (Bearish) |
| Trailing P/E | -9.01 |
| Market cap | 4.30B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-29 |
Available research for VKTX
Covered Call on VKTX: how it works, illustrative setup around the real 31.98 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on VKTX: how it works, illustrative setup around the real 31.98 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on VKTX: how it works, illustrative setup around the real 31.98 USD price, max profit/loss, breakeven and when to use it. Educational.
VKTX technical analysis: range, last 31.98 USD, RSI 42.3, 52w range 29.04 USD–42.79 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is VKTX in?
Viking Therapeutics (VKTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is VKTX in an uptrend or downtrend?
As of 2026-09-11, VKTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is VKTX's trailing P/E ratio?
VKTX's trailing P/E is -9.01, with a market cap of 4.30B. See the earnings research page for full valuation detail.
When does VKTX next report earnings?
VKTX is next scheduled to report earnings on 2026-07-29, with a consensus EPS estimate of -1.21 USD.